Holen Sie sich die Stockscreener-App
1.80
8.16%
-0.16
Handel nachbörslich:
1.80
Regulus Therapeutics Inc Aktie (RGLS) Neueste Nachrichten
IMPORTANT EQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
microRNA Pioneer Regulus Takes Center Stage: CEO to Reveal Latest Developments at Elite Biotech Summit - Stock Titan
Regulus Therapeutics Leads The Charge Among 3 Promising Penny Stocks - simplywall.st
Wells Fargo & Company Upgrades Regulus Therapeutics (NASDAQ:RGLS) to “Overweight” - Defense World
Wells Fargo Upgrades Regulus Therapeutics (RGLS) - Nasdaq
Regulus Therapeutics (RGLS) Announces Promising Phase 1b Trial R - GuruFocus.com
Regulus stock jumps after Phase 1 data update (RGLS:NASDAQ) - Seeking Alpha
Wells Fargo Upgrades Regulus Therapeutics to Overweight From Equalweight, $6 Price Target; Share Rise - MarketScreener
Regulus Therapeutics Completes Phase 1b Farabursen Study in Polycystic Kidney Disease - Marketscreener.com
Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease - Benzinga
Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews
Regulus Therapeutics (RGLS) Announces Successful Completion of its Phase 1b MAD Clinical Trial of Farabursen (RGLS8429) for the Treatment of ADPKD - StreetInsider
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose Clinical Trial of Farabursen for the Treatment of Autosomal Dominant Polycystic Kidney Disease - MarketScreener
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Quantisnow
Regulus Announces Positive Phase 1b Study Results - TipRanks
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Dis - StreetInsider.com
Game-Changing Clinical Data: New Drug Stops Kidney Disease Progression in Phase 1b Trial - Stock Titan
Regulus Therapeutics Inc. (NASDAQ:RGLS) Holdings Lowered by Victory Capital Management Inc. - Defense World
Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now - Insider Monkey
Regulus Therapeutics (NASDAQ:RGLS) Receives Buy Rating from Canaccord Genuity Group - Defense World
HC Wainwright Reaffirms “Buy” Rating for Regulus Therapeutics (NASDAQ:RGLS) - Defense World
10 Best Short-Term Stocks to Buy Now with Rebound Potential - Insider Monkey
Is Regulus Therapeutics (NASDAQ:RGLS) In A Good Position To Invest In Growth? - Yahoo Finance
Regulus Therapeutics Reports Positive Trial Results and Financials - TipRanks
Regulus: Q4 Earnings Snapshot - Bakersfield.com
Regulus Therapeutics Q4 Operating Expenses USD 13.746 Million -March 13, 2025 at 05:37 pm EDT - Marketscreener.com
Regulus Therapeutics Inc. SEC 10-K Report - TradingView
Regulus: Q4 Earnings Snapshot -March 13, 2025 at 04:19 pm EDT - Marketscreener.com
Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates - PR Newswire
Regulus Therapeutics (RGLS) to Release Quarterly Earnings on Thursday - Defense World
Rhumbline Advisers Lowers Stock Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock Position Cut by Rhumbline Advisers - The AM Reporter
AKPKD Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | AceLink Therapeutics, Sanofi, DiNAQOR AG, Poxel, AceLink Therapeutics, Regulus Therapeutics, Reata Pharma - Barchart
AKPKD Pipeline 2024: Key Companies, MOA, ROA, and Clinical - openPR
Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference - PR Newswire
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Regulus Therapeutics’ (RGLS) Buy Rating Reiterated at HC Wainwright - Defense World
RNAi Therapeutics and Technology Market Top Companies Study - openPR.com
Promising Phase 1b Results and FDA Alignment Drive Buy Rating for Regulus Therapeutics - TipRanks
Polycystic Kidney Disease Pipeline 2025: FDA Approvals - openPR.com
Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
10 Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average PT from Analysts - MarketBeat
Pre-market Movers In Healthcare Sector: ACER, AZRX, RUBY, ADTX, RGLS… - RTTNews
Checking in on Regulus Therapeutics Inc (RGLS) after recent insiders movement - Knox Daily
Is Regulus Therapeutics Inc (NASDAQ: RGLS) Stock Worth Investing In for High Returns? - Marketing Sentinel
RGLS’s price-to-free cash flow ratio: A closer look at its relevance - US Post News
Regulus Therapeutics Inc (RGLS) Stock: A Year of Highs and Lows - The InvestChronicle
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Morningstar
Regulus Management Takes Center Stage at Major Healthcare ConferenceKey Details Inside - Stock Titan
Regulus Therapeutics Inc. (NASDAQ:RGLS) Director David Baltimore Acquires 19,610 Shares - MarketBeat
Insider Buying: Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Acquires 50,000 Shares of Stock - MarketBeat
JPMorgan Chase & Co. Raises Stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Insider Moves Spark Interest: Is Regulus Therapeutics Set for a Comeback? - Jomfruland.net
Insiders Give Up US$8.7k As Regulus Therapeutics Stock Drops To US$1.00 - Yahoo Finance
CEO & Director of Regulus Therapeutics Joseph Hagan Buys 24% More Shares - Simply Wall St
Insider Buying: Joseph Hagan Acquires 50,000 Shares of Regulus T - GuruFocus
Insider Buying: David Baltimore Acquires Shares of Regulus Thera - GuruFocus.com
Regulus stock tumbles 24% amid study, regulatory updates - MSN
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):